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Background: Several well-established tumour prognostic factors are used to guide the clinical management of
patients with breast cancer. Lymphovascular invasion and angiogenesis have also been reported to have some
promise as prognostic factors. The aim of the present study was to examine the prognostic value of tumour
lymphovascular invasion and microvessel density compared with that of established prognostic factors in invasive
ductal breast cancer.
Methods: In addition to hormone receptor status and Ki-67 proliferative activity, lymphovascular invasion and
microvessel density and their relationship with survival were examined in patients with invasive ductal breast
cancer. Full sections and tissue microarrays (n = 384 patients) were utilised to assess these factors and were scored
by appropriate methods.
Results: On univariate analysis tumour size (P < 0.05), lymph node involvement (P < 0.01), lymphovascular invasion
(P < 0.05), microvessel density (P < 0.05) and local- regional treatment (P < 0.01) were associated with poorer survival
in ER negative tumours. On multivariate analysis in ER negative tumours lymph node involvement (P < 0.01) and
local- regional treatment (P < 0.05) were independently associated with poorer cancer-specific survival. On univariate
analysis tumour grade (P < 0.05), lymph node involvement (P < 0.001), HER-2 (P < 0.05), Ki-67 (P < 0.01) and
lymphovascular invasion (P < 0.001) were associated with poorer survival in ER positive tumours. On multivariate
analysis lymph node involvement (P < 0.001), Ki-67 (P < 0.001) and lymphovascular invasion (P < 0.05) were
independently associated with poorer cancer-specific survival in ER positive tumours.
Conclusion: Lymphovascular invasion but not microvessel density was independently associated with poorer
survival in patients with ER positive but not ER negative invasive ductal breast cancer.
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Breast cancer is the commonest cancer and the leading
cause of cancer death in women accounting for 22% of
all female cancers [1]. Although approximately 80% of
the 42,000 women in the UK are diagnosed with breast
cancer each year and survive at least five years [2], it is
still the leading cause of cancer death in women.
Prognostic factors aid clinical decision making, treat-
ment selection for individual patients and allow com-
parisons between groups of patients at risk of recurrence
or death. Clinically useful prognostic/predictive factors
should have biological relevance, be reproducible in differ-
ent laboratories, be validated prospectively in large series
of patients, be confirmed independently by other workers
and have threshold levels that are already optimized [3].
With reference to breast cancer, well-established
clinicopathological indicators of clinical outcome and
response to therapy are age, histologic type, grade,
tumour size, lymph node status and hormone recep-
tor expression [4,5]. Expression of oestrogen receptor
(ER) and progesterone receptor (PR) is associated with
better survival and response to oestrogen competive ago-
nists such as tamoxifen, independently of other variables
[4,6-10]. More recently, human epidermal growth factor
receptor 2 (HER-2) status has become an established
clinicopathological indicator of breast cancer clinical
outcome and response to therapy [4,5]. Proliferation is
recognised to be a key feature of tumour progression and
is now widely estimated by the nuclear antigen Ki-67,
which is tightly linked to the cell cycle. Several recent
studies have reported an association between higher Ki-67
proliferative activity and poorer recurrence-free [11-13]
and cancer-specific survival [14-16].
Lymphovascular invasion is a crucial step in the
complex process of tumour metastasis and an import-
ant criterion for further therapy. The presence of carcin-
oma cells in either lymphatic vessels (lymphatic invasion),
blood vessels (vascular invasion) or both (lymphovascular
invasion) is a significant prognostic factor in invasive
breast cancer, with respect to local and distance recur-
rence [17-22] and poorer survival [19-25]. At the St.
Gallen meeting in 2005, lymphovascular invasion was
recognised as a prognostic factor for node-negative
patients [26]. Node-negative patients with lymphovas-
cular invasion had higher breast cancer mortality rate
(53%) compared with patients with no lymphovascular
invasion (29%) [27]. Lymphovascular invasion is also
associated with other strongest prognostic factors in-
cluding tumour size, grade and loco- regional lymph
node involvement [21,27,28].
The role of angiogenesis (development of new capillaries
from pre-existing vessels) in the growth of solid tumours
is recognized [29]. Furthermore, it is a vital not only for
the development and progression of primary carcinomasbut also for invasion and metastasis of solid tumours [30].
Accumulating evidence indicate that progressive tumour
growth is dependent on angiogenesis [31] and several stud-
ies have reported an association between microvessel dens-
ity and poorer recurrence- free [23,32-37], cancer- specific
survival [16] and overall survival [16,23,32,34,35,38].
Microvessel density is also associated with a poorer clin-
ical response to chemotherapy [39] and to endocrine
therapy [39,40]. On the other hand, some authors do
not find any association between microvessel density and
recurrence- free survival and overall survival [41,42]
and one found a direct association between microvessel
density and clinical response to chemotherapy [43]. To
date there have been few studies that have directly com-
pared these different approaches and their relationship
with outcome. Moreover, it is not clear whether angiogen-
esis, as measured by microvessel density, may add add-
itional prognostic information to established prognostic
and predictive factors. Therefore, the aim of the present
study was to examine the prognostic value of lymphovas-
cular invasion and microvessel density and compare it
with other well-established clinicopathological prognostic
factors.
Methods
Patients presenting with invasive breast cancer at Glasgow
Royal and Western Infirmaries and Stobhill Hospital,
all in the West of Scotland, between 1995 and 1998 and
who had lymphovascular invasion assessed were studied
(n = 384). Available clinicopathological data included
age, histological tumour type, grade, tumour size, lymph
node status, type of surgery and use of adjuvant treatment
(chemotherapy, hormonal therapy and/or radiotherapy).
The study was approved by the Research Ethics Committee
of the North Glasgow University Hospitals NHS Trust.
Tissue micro array (TMA) construction
Tissue microarrays (TMA) were used in this study. In
brief, each specimen had tumour rich area identified by
a pathologist and 3 cores 0.6-mm2 tumour cores were
used to construct the TMA [44].
Assessment for tumour ER, PR and HER-2 statuses and
Ki-67 proliferative index
Tissue microarrays (TMA) were utilized to assess Oestrogen
(ER), progesterone (PR) status and HER-2 status as previ-
ously described [45,46] and to assess Ki-67 proliferative
activity as previously described [47]. Also TMA were used
to assess microvessel density by immunohistochemistry
for CD34 +.
Immunohistochemistry for microvessel density
In addition to TMA, Immunoreactivity to anti-CD34+
antibody was determined in 33 cases by using full-face
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full-face tissue sections and TMAs were stained for
CD34+. Sections and cores were dewaxed and rehydrated
for antigen heat-retrieval in Tris EDTA buffer (pH 8),
under pressure for 7 minutes. Endogenous peroxidise
was blocked by incubation in 3% hydrogen peroxide for
20 minutes. Arrays were then incubated in normal horse
serum 1:10 for 30 minutes at 25°C to block non- specific
binding. The primary antibody (Monoclonal mouse anti-
human, CD34+ Class II, Clone QBEnd 10, Code M7165,
DAKO, Glostrup, Denmark) dilutied 1:150 was applied for
30 minutes at 25°C with detection using Envision (DAKO
code K5007, Glostrup, Denmark) and DAB (3-3′ diamino-
benzidine, Vector code SK 4001, USA) according to man-
ufacturer’s instruction. Arrays were lightly counterstained
with haematoxylin, dehydrated and mounted in DPX. Sec-
tions of tonsil were used as positive and negative controls
for each staining batch as tonsil has many CD34+ cells.
Slide scanning and scoring
Stained slides were scanned using a Hamamatsu
NanoZoomer (Hertfordshire, UK). Visual counting of
vessel was performed on a computer monitor.
Lymphovascular invasion
Lymphovascular invasion was assessed by using a hematoxylin
and eosin on full sections. Blood and lymphatic vessel in-
vasion was not distinguished. Lymphovascular invasion
was recorded as present or absent.
Assessment of tumour microvessel density
Microvessel counting was a modification of the method
described by Weidner et al. (1992) in which large micro-
vessels as well as any single stained endothelial cells
clearly separated from adjacent microvessels, tumour
cells, and other connective tissue elements were consid-
ered single, countable microvessels. Branching structures
were counted as one, unless there was a break in con-
tinuity, in which case it was counted as two distinct ves-
sels [37].
The mean vessel count for the three cores of each
tumour sample was used for subsequent analysis. One
hundred eighty nine cores, counted independently by
two observers (C.O. and Z.M.) blinded to patient out-
come and the other observer’s score, yielded an inter-
class correlation coefficient (ICCC) of 0.96, indicating
excellent agreement. Z.M. subsequently scored all slides.
Accuracy of scoring depends on individual cores con-
taining a satisfactory sample of tumour cells, which was
checked by a qualified pathologist (J.J.G.). As there are
no universally accepted prognostic thresholds for micro-
vessel counts (CD34+), survival analysis was undertaken
using tertiles. In the full-face tissue sections, CD34+ was
counted in three x40 fields and the mean for the threefields was calculated. The mean for the three fields in
full-face sections was compared with the mean of three
cores in TMA for the same patients. The ICCC was
0.87, which indicates excellent agreement.
Statistical analysis
Inter-relationships between variables were assessed using
contingency tables with the chi-squared test for trend as
appropriate. Univariate analysis and multivariate survival
analysis with calculation of hazard ratios (HR) were per-
formed using Cox’s proportional-hazards model. A step-
wise backward procedure was used to derive a final
model of the variables that had a significant independent
relationship with survival. Deaths up to March 2010
were included in the analysis. Inter-relationships be-
tween methods were assessed using contingency table
analysis with the chi-squared test for trend as appropri-
ate. Because of the number of statistical comparisons, a
P value <0.01 was considered to be significant All statis-
tical analysis was performed using SPSS software version
19 (SPSS Inc., Chicago, IL, USA).
Results
The clinicopathological characteristics of 384 patients
with primary operable breast cancer are shown in Table 1.
The relationship between ER status and clinico-
pathological characteristics is shown in Table 2. Patients
with ER negative tumours were younger (P < 0.01), had
larger carcinomas (P < 0.01), of higher tumour grade
(P< 0.001), more likely to be PR negative tumours (P< 0.001),
more likely to be HER-2 positive tumours (P < 0.001), with
more lymphovascular invasion (P < 0.001). They were also
more likely to receive systemic adjuvant treatment in the
form of chemotherapy (P < 0.001) and had a shorter
cancer- specific survival (P < 0.001).
The minimum follow-up was 142 months; the median
follow-up of the survivors was 165 months. In the pa-
tients with ER negative tumours 58 patients developed
recurrence, 8 local, 38 distant and 4 both, 79 patients
died, 48 of their disease. In the ER positive tumours, 46
patients developed recurrence, 9 local, 31 distant and 1
both, 120 patients died, 47 of their disease.
The relationship between clinico-pathological charac-
teristics of patients with ER negative primary operable
invasive ductal breast cancer and recurrence- free sur-
vival was examined. On univariate survival analysis
tumour size (HR 2.70, 95% CI 1.43-5.09, P = 0.002),
lymph node involvement (HR 1.71, 95% CI 1.17-2.50,
P = 0.006), lymphovascular invasion (HR 2.71, 95% CI
1.34-5.50, P = 0.006), microvessel density (HR 1.57,
95% CI 1.06-2.34, P = 0.026) and local-regional treatment
(HR 2.29, 95% CI 1.08-4.87, P = 0.032) were significantly
associated with recurrence- free survival. On multivariate
survival analysis, tumour size (HR 2.27, 95% CI 1.19-4.36,
Table 1 The clinico-pathological characteristics of patients with primary operable invasive ductal breast cancer (n =
384)
Clinico-pathological characteristics Patients (n)
Age (≤50/>50 years) 107 (28%)/277 (72%)
Size (≤20/21-50/≥50 mm) 218 (57%)/154 (40%)/11 (3%)
Grade (I/II/III) 70 (18%)/157 (41%)/157 (41%)
Involved lymph node (0/1-3/>3) 205 (53%)/108 (28%)/66 (17%)
Oestrogen -receptor status (ER-/ER+) 124 (32%)/237 (62%)
Progesterone -receptor status (PR-/PR+) 193 (50%)/170 (44%)
HER-2 status (HER-2 -/HER-2+) 299 (78%)/65 (17%)
Ki-67 status (Low Ki-67/High Ki-67) 272 (71%)/92 (24%)
LVI (Absent/Present) 234 (61%)/150 (39%)
MVD (CD34+) (tertiles 1, 2, 3) 137 (36%)/126 (33%)/106 (28%)
Loco-regional treatment (Lumpectomy + radiotherapy/mastectomy + radiotherapy) 142 (37%)/242 (63%)
Systemic treatment (ER-based treatment) (hormonal/hormonal + chemotherapy/chemotherapy/none) 192 (50%)/86 (22%)/80 (21%)/22 (6%)
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1.10-5.01, P = 0.028) were independently associated with
recurrence- free survival.
The relationship between clinicopathological charac-
teristics of patients with ER negative primary operable
invasive ductal breast cancer and cancer- specific sur-
vival is shown in Table 3. On univariate survival ana-
lysis tumour size (P < 0.05), lymph node involvement
(P < 0.01), lymphovascular invasion (P < 0.05), micro-
vessel density (P < 0.05) and loco-regional treatment
(P < 0.01) were significantly associated with cancer-
specific survival. On multivariate survival analysis, lymph
node involvement (P < 0.01) and loco-regional treatment
(P < 0.05) were independently associated with cancer-
specific survival.Table 2 The relationship between clinico-pathological charac




Involved lymph node (0/1-3/>3)
Progesterone -receptor status (PR-/PR+)
HER-2 status (HER-2 -/HER-2+)
Ki-67 status (Low Ki-67/High Ki-67)
LVI (Absent/Present)
MVD (CD34+) (tertiles 1, 2, 3)
Loco-regional treatment (Lumpectomy + radiotherapy/mastectomy + radioth
Systemic treatment (ER-based treatment) (hormonal/hormonal +
chemotherapy/chemotherapy/none)
Cancer specific survival (months)*
*Mean (95% CI).The relationship between clinicopathological charac-
teristics of patients with ER positive primary operable in-
vasive ductal breast cancer and recurrence- free survival
was examined. On univariate survival analysis, tumour
grade (HR 1.89, 95% CI 1.12-3.17, P = 0.017), lymph node
involvement (HR 2.42, 95% CI 1.55-3.76, P < 0.001), HER-
2 status (HR 2.90, 95% CI 1.25-6.72, P = 0.013), Ki-67 pro-
liferative activity (HR 3.01, 95% CI 1.50-6.04, P = 0.002),
lymphovascular invasion (HR 3.83, 95% CI 1.89-7.77,
P ≤ 0.001), microvessel density (HR 1.70, 95% CI 1.05-2.73,
P = 0.030) and systemic treatment (HR 1.59, 95% CI
1.09-2.32, P = 0.017) were significantly associated with
recurrence- free survival. On multivariate survival
analysis, lymph node involvement (HR 2.15, 95% CI
1.35-3.44, P = 0.001) and Ki-67 proliferative activity (HRteristics and ER status of patients with primary operable
Oestrogen receptor
negative (n = 124)
Oestrogen receptor











erapy) 44/80 89/148 0.699
26/19/66/11 158/61/8/8 <0.001
130 (118–142) 156 (150–162) 0.001
Table 3 The relationship between clinico-pathological characteristics of patients with ER negative primary operable
invasive ductal breast cancer and cancer- specific survival
Univariate survival analysis Multivariate survival analysis
Cancer-specific survival Cancer-specific survival
Hazard ratio P-value Hazard ratio P-value
(95% CI) (95% CI)
Age (<50/>50 years) 0.78 (0.42-1.47 0.448
Size (≤20/21-50/>50 mm) 2.19 (1.14-4.22) 0.018 0.116
Grade (I/II/III) 1.30 (0.63-2.72) 0.478
Involved lymph node (0/1-3/>3) 1.85 (1.24-2.66) 0.001 1.71 (1.17-2.50) 0.006
Progesterone -receptor status (PR-/PR+) 0.05 (0.00-22.73) 0.330
HER-2 status (HER-2 -/HER-2+) 1.26 (0.66-2.41) 0.489
Ki-67 status (Low Ki-67/High Ki-67) 1.48 (0.70-3.11) 0.305
LVI (Absent/Present) 2.14 (1.08-4.22) 0.029 0.428
MVD (CD34+) (tertiles 1, 2, 3) 1.62 (1.08-2.44) 0.021 0.130
Loco-regional treatment (Lumpectomy + radiotherapy/
mastectomy + radiotherapy)
3.27 (1.44-7.42) 0.005 2.64 (1.14-6.09) 0.023
Systemic treatment (ER-based treatment) (hormonal/
hormonal + chemotherapy/chemotherapy/none)
1.00 (0.70-1.42) 1.00
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sociated with recurrence- free survival.
The relationship between clinicopathological characteris-
tics of patients with ER positive primary operable invasive
ductal breast cancer and cancer- specific survival is shown
in Table 4. On univariate survival analysis tumour size
(P < 0.01), tumour grade (P < 0.05), lymph node involve-
ment (P < 0.001), Ki-67 proliferative activity (P < 0.001),
lymphovascular invasion (P < 0.001) and systemic treatment
(P < 0.05) were significantly associated with cancer- specificTable 4 The relationship between clinico-pathological charac





Age (<50/>50 years) 1.82 (0.77-4.3
Size (≤20/21-50/>50 mm) 2.04 (1.20-3.4
Grade (I/II/III) 1.71 (1.09-2.6
Involved lymph node (0/1-3/>3) 2.26 (1.54-3.3
Progesterone -receptor status (PR-/PR+) 0.72 (0.38-1.3
HER-2 status (HER-2 -/HER-2+) 2.17 (0.96-4.8
Ki-67 status (Low Ki-67/High Ki-67) 3.71 (1.98-6.9
LVI (Absent/Present) 2.98 (1.62-5.4
MVD (CD34+) (tertiles 1, 2, 3) 1.41 (0.95-2.0
Loco-regional treatment (Lumpectomy + radiotherapy/
mastectomy + radiotherapy)
1.75 (0.90-3.4
Systemic treatment (ER-based treatment) (hormonal/
hormonal + chemotherapy/chemotherapy/none)
1.45 (1.03-2.0survival. On multivariate survival analysis, lymph node
involvement (P < 0.01), Ki-67 proliferative activity (P <
0.001) and lymphovascular invasion (P < 0.05) were inde-
pendently associated with cancer- specific survival.
The inter-relationships between clinicopathological char-
acteristics for patients with ER negative primary operable
invasive ductal breast cancer are shown in Table 5. Age was
negatively associated PR status (P < 0.01). Increased tumour
size was positively associated with more involved lymph
node (P < 0.01). Involved lymph node was positivelyteristics of patients with ER positive primary operable
te survival analysis Multivariate survival analysis
r-specific survival Cancer-specific survival





2) <0.001 2.11 (1.40-3.20) <0.001
7) 0.316
8) 0.062 0.109
6) <0.001 3.62 (1.88-7.00) <0.001




Table 5 Inter-relationships between the clinicopathological characteristics in patients with ER negative primary













(P-value) (P-value) (P-value) (P-value) (P-value) (P-value) (P-value) (P-value) (P-value) (P-value)
Age (≤50/>50 years) 0.241 0.908 0.242 0.002 0.154 0.772 0.826 0.347 0.282 0.059
Size (≤20/21-50/>50 mm) 0.181 0.004 0.131 0.343 0.085 0.011 0.106 0.042 0.151
Grade (I/II/III) 0.127 0.049 0.730 0.586 0.042 0.586 0.980 0.164
Involved lymph node
(0/1-3/>3)
0.166 0.058 0.392 <0.001 0.068 0.013 0.118
Progesterone –receptor
status (PR-/PR+)
0.769 0.985 0.111 0.191 0.093 0.272
HER-2 status
(HER-2 -/HER-2+)
0.949 0.001 0.340 0.068 0.292
Ki-67 proliferative activity
(Low Ki-67/High Ki-67)
0.739 0.651 0.256 0.335
LVI (Absent/Present) 0.414 0.054 0.563





Bold data reflects an association between the two variables.
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(P < 0.001). HER-2 status was positively associated with the
presence of lymphovascular invasion (P < 0.01).
The inter-relationships between clinicopathological
characteristics for patients with ER positive primary op-
erable invasive ductal breast cancer are shown in Table 6.Table 6 Inter-relationships between the clinicopathological ch






(P-value) (P-value) (P-value) (P-value)
Age (≤50/>50 years) 0.058 0.236 0.495 0.297
Size (≤20/21-50/>50 mm) 0.033 <0.001 0.879















Bold data reflects an association between the two variables.Age was negatively associated receiving systemic treat-
ment (P < 0.001). Increased tumour size was positively
associated with more involved lymph node (P < 0.001), the
presence of lymphovascular invasion (P < 0.001), and loco-
regional treatment (P < 0.001). Higher tumour grade was









(P-value) (P-value) (P-value) (P-value) (P-value) (P-value)
0.054 0.641 0.913 0.238 0.261 <0.001
0.826 0.041 <0.001 0.568 <0.001 0.438
<0.001 <0.001 <0.001 0.072 0.108 0.627
0.323 0.035 <0.001 0.607 0.001 0.013
0.002 0.340 0.392 0.997 0.256 0.804
0.020 0.119 0.627 0.363 0.603
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lymphovascular invasion (P < 0.001). Involved lymph
node was positively associated with the presence of
lymphovascular invasion (P < 0.001) and loco-regional
treatment (P < 0.01). The presence of PR was nega-
tively associated with HER-2 + status (P < 0.01). Ki-67
proliferative activity was positively associated with
microvessel density (P < 0.01).
Discussion
The results of the present study showed that lympho-
vascular invasion but not microvessel density was con-
sistently associated with poorer recurrence- free and
cancer-specific survival in both ER negative and ER posi-
tive tumours. The results of the present study also
confirmed that established tumour characteristics such
as tumour size, grade, nodal status, hormone status and
Ki-67 proliferative activity provide prognostic value. There-
fore, in the context of the present comprehensive examin-
ation of the prognostic value of tumour pathological
features, it can be concluded that lymphovascular invasion
may have an important role in determining outcome in pa-
tients with primary operable invasive ductal breast cancer.
The results of the present study are consistent with the
previous studies that reported prognostic value of the lym-
phovascular invasion independent of involvement lymph
node as well as other tumour characteristics such as grade,
PR and HER-2 status [19-22,25]. However, some studies
reported that the presence of LVI was not independently
associated with outcome in primary breast cancer [28,48]
and others reported no association [49,50].
The results of the present study are also consistent
with the previous studies that reported an association
between the microvessel density and poorer survival
[16,23,32-38]. However, in the present study it was of
interest that microvessel density was associated with
poorer survival in ER negative but not ER positive tu-
mours whereas lymphovascular invasion was associated
with poorer survival in both ER negative and ER positive
tumours. Therefore, it would appear that lymphovascu-
lar invasion process is more consistently associated with
poor outcome in patients with primary breast cancer.
The results of the present study are consistent with
the Hayes and co-workers that concluded microvessel
density alone could not be recommended as a basis for
clinical decision making [51]. However, Kato and co-
workers (2003) concluded that microvessel density, by
various methods, did offer additional prognostic value to
lymphovascular invasion and provided more reliable
prognostic information than lymph node status [24].
In this context, it was of interest that in the present
study there was an association between increased lym-
phovascular invasion and lymph node involvement in
both ER negative and ER positive tumours. Also, inpatients with ER positive tumours there was an associ-
ation between lymphovascular invasion, tumour size and
tumour grade. In contrast, angiogenesis (MVD) was only
associated with Ki-67 proliferative activity. Taken to-
gether, these results are consistent with the hypothesis a
proliferating tumour promotes angiogenesis, lymphovas-
cular invasion, nodal involvement and metastases and
then subsequent poor survival. Therefore, it may be that
angiogenesis is essential for tumour growth whereas
lymphovascular invasion is essential for the tumour to
metastasise. Consistent with this hypothesis, in the smal-
lest tumours (<10 mm, n = 66) angiogenesis was observed
in 83% of patients and lymphovascular invasion was ob-
served in 29% of patients. In contrast, nodal involvement
was only present in 23% of patients. The basis of these as-
sociations of lymphovascular invasion, angiogenesis and
poorer cancer outcome in ductal breast cancer is not clear
but may involve the tumour inflammatory cell infiltrate
[52]. Therefore, further work is required to examine these
potential relationships. Irrespective, it is apparent that
lymphovascular invasion and angiogenesis are not isolated
pathological features but are strongly related to other ag-
gressive tumour characteristics. To minimize the risk of
measurement bias, two independent observers examined
the same cores before assigning an overall score. High
levels of independent inter-observer agreement in the as-
sessment of CD34+ suggest that this technique is reliable.
There is limitation of whether a small core sample
used in the present TMA was representative of the en-
tire tumour was examined, using a pilot comparison
study of at 33 full-faced breast cancer tissue sections.
Conclusions
In conclusion, lymphovascular invasion and to a lesser
extent microvessel density add prognostic value to the
established clinical pathological features in patients with
primary operable invasive breast cancer.
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